spacer
home > ebr > autumn 2018 > produce potential
PUBLICATIONS
European Biopharmaceutical Review

Produce Potential

Custom-made oligonucleotides are commonly produced by solid phase synthesis, where the sequence is grown chemically on a resin in a 3’-5’ direction (1). Each amidite/nucleotide monomer has a 5’ trityl-blocking group to prevent addition of more than one nucleotide in each synthesis step that is cleaved off prior to the start of next coupling reaction (2). The completed oligonucleotide is released from the solid support by ammonolysis. Although the solid-phase technology gives a very low synthesis error rate, a small percentage of sequences where the oligonucleotide has deletions are always present, such as N-1 sequences and depurinations (where the nucleic base has been cleaved off), or extra insertions of elements (eg, N+1) (3). The frequency of failures increases with length of the synthesised oligonucleotide.

Antisense oligonucleotides (ASOs) are DNA sequences designed to bind complementary RNA targets (mainly mRNAs) to affect gene expression. Antisense gene therapy is emerging as one of the most promising therapeutics for various diseases, such as cancer (4-5). As of 2017, six FDAapproved ASO-based therapies are on the market, and many are in clinical trials (6). Most of the ASO molecules currently in clinical trials are phosphorothioates: modified nucleic acids in which one of the non-bridging oxygens on the phosphate backbone is replaced by a sulphur (7). This modification increases the half-life of the oligonucleotide. In addition to the mentioned synthesis errors, the phosphorothioate linkage of phophorotioates might be oxidised to a phosphodiester linkage, (P=O)x.

Due to the stringent requirements in therapeutic applications, efficient purification schemes to produce oligonucleotides with a minimum of erroneous sequences are a necessity.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Cecilia Unoson is a Senior Application Scientist at Bio-Works Technologies and has a PhD from the Department of Cellular and Molecular Biology at Uppsala University, Sweden. Cecilia has 15 years’ experience working with oligonucleotides, especially within the RNA field, where she has focussed on regulatory RNAs and the CRISPR-Cas9 system. She also has a strong background in proteomics and has worked in both small and large biotech companies. Today, Cecilia is responsible for the oligonucleotide applications at Bio-Works Technologies.

Dr Lars Haneskog is the R&D director at Bio-Works Technologies, with a PhD in bioseparation and membrane proteins from Uppsala University, Sweden. The research focus was bioseparation and membrane proteins. He has more than 20 years of experience in chromatographic purification of biomolecules, and development of chromatography products.
spacer
Dr Cecilia Unoson
spacer
spacer
spacer
Dr Lars Haneskog
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

A New Era for Faster s.r.l. Air Safety Products in the UK.

In November 2018, Biopharma Group became the exclusive distributor of Italian brand, Faster S.r.l.’s clean air and laboratory range of products within mainland UK.
More info >>

White Papers

By Your Side for a Healthier World

West Pharmaceutical Services, Inc.

Every day, injectable drugs are administered to improve the lives of millions of patients around the world. And every day, West is working by your side to design and manufacture drug packaging and delivery systems that will bring our customers’ drugs from concept to the patient more efficiently, reliably and safely. West understands our customers’ challenges and helps with solutions every step of the way, with cutting-edge production technologies, an unmatched expertise in global regulatory compliance, and an ever-growing knowledge base of pharmaceutical drug product testing, development, packaging and delivery. Whether focused on one piece of the process or an end-to-end solution, West is by your side for a healthier world.
More info >>

 
Industry Events

SMi Presents the 11th Adaptive Designs in Clinical Trials Conference 2019

1-2 April 2019, Holiday Inn Kensington Forum, London

SMi Group are proud to announce the 11th annual Adaptive Designs in Clinical Trials conference and exhibition will return to London from the 1st – 2nd April 2019. With the growing popularity in use and acceptance of adaptive designs in clinical trials - demonstrated most recently with the new FDA draft guidance on adaptive designs – there is a pressing need for a forum which explores this increasingly normalized medical methodology.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement